Management of Recurrent Gouty Arthritis Attacks

Introduction to Management

The American College of Physicians recommends urate-lowering therapy with prophylaxis for patients with recurrent gouty arthritis attacks (≥2 episodes per year) after discussing benefits, harms, costs, and individual preferences with the patient 1, 2, 3

For acute gout attacks, first-line treatments include NSAIDs, low-dose colchicine, or corticosteroids, with selection based on patient-specific factors such as cost, contraindications, and comorbidities 3, 4
Low-dose colchicine (1.2 mg followed by 0.6 mg 1 hour later) is as effective as higher doses with fewer gastrointestinal side effects 1, 3

Urate-lowering therapy (ULT) should be initiated in patients with recurrent gout (≥2 episodes per year), problematic gout, or serum urate levels >476 µmol/L (>8 mg/dL) 1, 2, 3
Febuxostat (40 mg/day) is equally effective as allopurinol (300 mg/day) at decreasing serum urate levels 2
Moderate to high-quality evidence shows ULT reduces risk for acute gout attacks after 1 year, but not within the first 6 months of treatment 2, 5
Patients achieving serum urate levels <6.0 mg/dL have fewer gout flares at 12 months 6, 5

Prophylaxis with low-dose colchicine or low-dose NSAIDs should always be provided when initiating ULT to prevent acute flares, and continued for more than 8 weeks 2, 5, 7
The rate of acute gout flares approximately doubles when anti-inflammatory prophylaxis is discontinued after 8 weeks 6, 5

Serum urate levels should be monitored to achieve a target of <6 mg/dL (357 µmol/L) 6, 5
Patients who attain urate levels <6.0 mg/dL have fewer gout flares at 12 months than those with higher levels 6, 5
Duration of ULT is typically long-term, though insufficient evidence exists regarding when/if to discontinue therapy 2
One cohort study suggests ULT might be discontinued in asymptomatic patients who maintained serum urate levels <7 mg/dL after 5 years of treatment 6

Failure to provide prophylaxis when starting ULT significantly increases the risk of acute flares 7, 5
Discontinuing prophylaxis too early (before 8 weeks) increases risk of breakthrough attacks 2, 6
Rapid lowering of urate levels can paradoxically increase gout flares in the first 6 months due to mobilization of urate crystals from tissue deposits 5